• Protease Inhibitor Cocktail: MS-SAFE Protocol

  2026-09-03

  Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) helps limit endogenous proteolysis during cell and tissue protein extraction while avoiding AEBSF-related concerns in mass spectrometry workflows. It is appropriate for protease control in lysates, but metalloproteinase and phosphatase control require separate validation or supplementation.

• M344: Practical Histone Deacetylase Inhibitor Workflows

  2026-09-03

  M344 combines cell permeability with strong HDAC pathway control for cancer-cell proliferation, differentiation, apoptosis, migration, and radiation-response studies. This practical guide translates its neuroblastoma findings into reproducible dose–time designs, assay choices, and troubleshooting decisions.

• ICG001: Wnt/β-Catenin Pathway Inhibitor

  2026-09-02

  ICG001 is a selective Wnt/β-catenin pathway inhibitor that disrupts β-catenin recruitment of CBP without directly targeting p300. Its reported 3 µM transcriptional IC50 and activity in colon carcinoma, glioblastoma stem-cell, and fibrosis models make it a useful research tool, not an established clinical therapy.

• Flavopiridol (L868275): CDK Workflow Guide

  2026-09-02

  Flavopiridol (L868275) enables controlled pan-CDK perturbation for cell-cycle, apoptosis, transcription, and tumor-model studies. This guide separates established cancer research applications from exploratory use as a comparator in endoplasmic-reticulum-stress and intestinal stem-cell assays.

• SIRT1, Resveratrol, and Mitochondrial Biogenesis

  2026-09-01

  Zhao and colleagues identify a SIRT1–PGC-1α–TFAM axis that links prion peptide toxicity to defective mitochondrial biogenesis in N2a neuroblastoma cells. Their data position resveratrol as a pharmacological SIRT1 activator that partially restores mitochondrial function and limits apoptosis in this cellular model, while also defining important boundaries for interpretation and translation.

• Dopamine, cAMP/PKA, and Osteoclast Differentiation

  2026-09-01

  Wang et al. identify a D2R/cAMP/PKA/CREB axis through which dopamine suppresses osteoclast differentiation, connecting neurotransmitter signaling with bone-resorbing cell biology. The study supports pathway-level validation using receptor, second-messenger, phosphorylation, and differentiation readouts while emphasizing that the mechanism remains primarily an in vitro finding.

• SFRP1, Neutrophils, and Wnt Signaling in Oral Fibrosis

  2026-08-31

  The reference study identifies reduced SFRP1 as a possible molecular link between neutrophil infiltration, Wnt/β-catenin activation, and fibrosis in an arecoline-induced oral submucous fibrosis model. Its combination of tissue correlation, SFRP1 overexpression, and pathway-rescue experiments provides a useful framework for testing causal relationships, while remaining preliminary for clinical translation.

• Caffeine Workflows for Cancer and Metabolism

  2026-08-31

  Build reproducible Caffeine experiments around sarcoma cell line inhibition, VPA combination testing, and energy-balance studies in diet-induced obesity mouse models. This guide also shows how ALDH2 ischemia research can strengthen assay controls without implying that Caffeine is an ALDH2 activator or cardiovascular therapy.

• From Cell Death Signals to Translational Decisions

  2026-08-30

  A mechanistic and workflow-focused perspective on using AO/PI fluorescence to distinguish viable, apoptotic, and membrane-compromised cells, while positioning the assay within melanoma research, orthogonal validation, and translational decision-making.

• G-1: Selective GPR30 Agonist Workflow

  2026-08-29

  Build cleaner GPR30/GPER1 experiments with G-1, from rapid calcium and PIP3 assays to immune, cancer-migration, and cardiac models. This workflow emphasizes receptor-selective controls, DMSO handling, reference-study alignment, and practical troubleshooting.

• UTP Solution (100 mM) for RNA Assay Design

  2026-08-28

  Discover how UTP Solution supports controlled RNA synthesis while clarifying what nucleotide supply can—and cannot—reveal about TRIM66-mediated olfactory receptor regulation. This guide connects reagent selection, assay architecture, and interpretation across molecular biology and neuroepigenetics.

• LY2886721: BACE1 Inhibition in AD Research

  2026-08-28

  LY2886721 is an oral BACE inhibitor for mechanistic Alzheimer’s disease treatment research. Reported nanomolar activity, amyloid beta reduction in cellular and mouse models, and biomarker modulation support its use for studying BACE1 enzyme inhibition rather than as evidence of clinical efficacy.

• Pexmetinib (ARRY-614): A State-Aware Strategy

  2026-08-27

  Pexmetinib (ARRY-614) offers translational researchers a dual-pathway framework for connecting p38 MAPK signaling, Tie2 biology, cytokine output, and bone marrow disease models. This thought-leadership analysis combines product evidence with recent structural insights into kinase dephosphorylation to propose more discriminating assay designs, validation workflows, and translational decision points.

• Ganetespib (STA-9090): Hsp90 Research Guide

  2026-08-27

  Ganetespib, also called STA-9090, is a triazolone-containing small-molecule Hsp90 inhibitor for experimental cancer research. Product information links competitive N-terminal ATP-pocket binding with client-protein degradation and reports nanomolar cellular activity plus tumor regression in a mouse xenograft model.

• Psoralen-Induced Cholestasis via ERK1/2

  2026-08-26

  A 2024 Chemical Research in Toxicology study shows that psoralen and isopsoralen, estrogen-like constituents of Psoraleae Fructus, induce cholestatic liver injury in zebrafish larvae through altered bile-acid regulation and ERK1/2 activation. Pharmacological rescue with an ERK1/2 antagonist and exemestane links estrogenic signaling to the injury phenotype and provides a mechanistic framework for studying phytoestrogen-associated cholestasis.

8462 records 1/565 page Next 12345 下5页 Last page